View more on these topics

River and Mercantile fund managers to take hit from Mifid II decision


River and Mercantile says fund manager remuneration will take a hit when it absorbs research costs next month under Mifid II.

The boutique asset manager, which has AUM of £31bn, joins the majority in the industry in its decision to pay research costs itself under the EU directive, which comes into effect from 3 January.

River and Mercantile estimates the total yearly cost of the change will be between £1m and £1.5m, but that this will be partially offset by “a reduction in remuneration expense”, which refers to fund manager pay. The net impact to P&L will therefore be £700,000 to £1.1m. 

River and Mercantile head of asset management James Barham says: “The increase of costs associated with external research reduces the overall profitability of the business which impacts the underlying remuneration of the business.”

He says externally-sourced research forms a critical part of the in-house investment process and validates internal research outcomes. It is used alongside the asset manager’s proprietary screening process, MoneyPenny.

Barham says they will continue to use external research in a similar manner under Mifid II.

The EU directive requires the unbundling of external research and execution costs.

The majority of asset managers have confirmed they will absorb the separated cost of research from their own P&L, with Aberdeen Standard Investments, LGIM and Vanguard among the industry giants that have confirmed their intention to do so.

Europe’s largest asset manager Amundi this week announced a U-turn on its decision to pass the research bill on to clients, following in the footsteps of Schroders, Henderson and Invesco, which all reversed their initial Mifid II position.

Fidelity International is one of the few asset managers that will pass on costs to investors. The decision was revealed when the fund house announced its shake-up of charges, including a ‘fulcrum fee’.

French fund house Carmignac has also announced it will charge investors for research.



Doubts remain over asset manager preparedness for Mifid II

Experts have played down any immediate moves from the FCA towards those firms that are not prepared for Mifid II regulation that comes into force on 3 January 2018. However, concerns remain that a “material number” of small asset managers have not yet started preparing for the major European regulation. The FCA expects firms to […]


Asset managers expect to bear millions in Mifid II research costs

Asset managers could see the cost of analyst research averaging $10m for every $10bn of equity assets under management when the new Mifid II rules take effect in January. Under the new regulation, asset managers will be required to separate the cost of research from portfolio transaction costs. According to a survey by the CFA […]


Asset manager to hike fund fees on Mifid II costs

Boutique firm Crux Asset Management will increase the cost of some of its funds as it plans to continue to charge clients for research after Mifid II, Money Marketing can reveal. Despite many peers having decided to absorb the costs, at the start of November the firm, created by ex-Henderson Global Investors star fund manager […]


How do we solve the unregulated investments problem?

At our recent Money Marketing In Focus conference, the FCA and Financial Services Compensation Scheme shared a stage to talk about the fallout from the freedoms and where we go from here. It is clear the advisers in the audience were focused on one in issue in particular: how unregulated investments are treated. FSCS chief […]

Something chronic

Amanda Docherty, Senior Marketing Consultant, Royal London  I’ve just returned from a mini-break in Tenerife. Twenty girls on a hen weekend, so you can imagine there was a fair bit of eating, drinking and dancing. Although we did squeeze in a water park, boat trip and paddle boarding. It’s all about the balance!  There were a […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment